(NASDAQ: CNSP) Cns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.5%.
Cns Pharmaceuticals's earnings in 2026 is -$16,486,290.On average, 3 Wall Street analysts forecast CNSP's earnings for 2026 to be -$2,459,619, with the lowest CNSP earnings forecast at -$2,363,163, and the highest CNSP earnings forecast at -$2,531,960. On average, 3 Wall Street analysts forecast CNSP's earnings for 2027 to be -$2,474,525, with the lowest CNSP earnings forecast at -$2,377,485, and the highest CNSP earnings forecast at -$2,547,306.
In 2028, CNSP is forecast to generate -$2,802,475 in earnings, with the lowest earnings forecast at -$2,692,574 and the highest earnings forecast at -$2,884,900.